Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa

Journal of Hepatology

Volumn 31, Issue 4, 1999, Pages 612-617

  Naveau, Sylvie ⁱ   Balian, Axel ^j   Degos, Françoise ^a   Daurat, Véronique ^j   Chevret, Sylvie ^j   Gayno, Sophie ^b   Bastie, Anne ^c   Riachi, Ghassan ^d   Bartolomei Portal, Isabelle ^e   Barange, Karl ^f   Moussalli, Joseph ^g   Bailly, François ^h   Chaumet Riffaud, Philippe ^j   Emilie, Dominique ^j  

^a BEAUJON HOSPITAL   (France)

^b CENTRE HOSPITALIER RENÉ DUBOS   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

^f CHU PURPAN   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h HÔTEL DIEU   (France)

ⁱ Serv d'H   (France)

^j NONE

more..

Author keywords

Alfa interferon; Chronic hepatitis C; HCV RNA; Prognostic factors; Soluble interleukin 2 receptor

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0032884451     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80339-0     Document Type: Article

References (17)

1. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest. 7:1997;1472-1477.
2. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2 like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology. 25:1997;449-458.
3. Napoli J, Bishop GA, McGuinness PH, Painter DM, McGaughan GW. Progressive liver injury in chronic hepatitis C infection correlate with increased intra hepatic expression of Th-1 associated cytokines. Hepatology. 24:1996;759-765.
4. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med. 113:1990;619-627.
5. Rubin LA, Jay G, Nelson DL. The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol. 137:1986;3841-3844.
6. Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, et al. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. J Hepatol. 29:1998;224-232.
7. Yamaguchi S, Onji M, Ohta Y. Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases. Hepatogastroenterol. 35:1988;245-248.
8. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Ohmiya M, Tani Y, et al. Serum levels of soluble interleukin-2 receptors and effects of interferon α for patients with chronic hepatitis C virus. Dig Dis Sci. 40:1995;1837-1841.
9. Kawakami Y, Hayashi J, Ueno K, Ohmiya M, Kishihara Y, Yamaji K, et al. Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection. Fukuoka Igaku Zasshi. 88:1997;274-282.
10. Nelson DR, Marousis CG, Daves GL, Rice CM, Wong J, Houghton M, et al. The role of hepatitis C virus specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol. 158:1997;1473-1481.
11. Nelson DR, Marousis CG, Ghnot T, Davis GL, Lau JYN. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology. 28:1998;225-230.
12. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 112:1997;1017-1021.
13. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection pre and post treatment with interferon alfa. Hepatology. 24:1996;6-9.
14. Quiroga JA, Martin J, Pardo M, Carreno V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C and their relation to therapeutic response to interferon-α Dig Dis Sci. 39:1994;2485-2496.
15. Morishima I, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, et al. Serum levels of soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Scand J Gastroenterol. 30:1995;807-811.
16. Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa 2 b trials. Hepatology. 26:(suppl 1):1997;835-885.
17. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology. 27:1998;1149-1156.